common.study.topics.clinical

Testing Experimental Frontotemporal Dementia Medication

common.study.values.description

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin Mutation

A first in human phase 1 study in healthy volunteers and participants with Granulin mutation causative of frontotemporal dementia (FTD) to assess AL001 safety, tolerability, pharmacokinetics, and pharmacodynamics

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Biological - AL001

Active dose of AL001

Placebo

Saline solution administered as a single infusion as palcebo.

participant.views.study.view.additional

participant.views.study.view.scientific-title

A First in Human Phase 1 Study in Healthy Volunteers and in Participants With Frontotemporal Dementia (FTD) With Granulin Mutation

common.study.values.clinical-trial-id

NCT03636204

participant.views.study.view.id

bkRZNa